Coherent hyaluronic acid: a revolution in injectable cosmetology

Hyaluronic acid in injectable products of aesthetic cosmetology is designed to fill the tissue, restore the structure and create a lifting effect, and it also has excellent regenerative properties aimed at activating the processes of natural collagen production.

Each individual filler differs in anti-inflammatory, anesthetic properties, quality, degree of purification of hyaluronic acid, content of proteins, heavy metals and other components.

In the article estet-portal.com you can get acquainted in detail with the personal choice of a surgeon, a member of the German Society of Surgeons, the Society of Mesotherapy, the European Academy of Aesthetic Surgery and the International Society of Aesthetic Medicine, the author of scientific articles on volumetric facial modeling, Dr. Wolfgang Rare-Freedom (Wolfgang Redka-Swoboda, Germany).

What is the essence of the recent revolution in the field of injectable cosmetology

B. RS: BIOXIS Pharmaceuticals has introduced a completely new idea for the aesthetic medicine market, which concerns hyaluronic filler. Of course, if you are launching a new product, it must have key competitive advantages.

Long-chain hyaluronic acid in previously existing preparations had a 3D structure in the form of globules. BIOXIS has found that when the chains of hyaluronic acid are lengthened and ordered, the structure of the material becomes smoother, more homogeneous and coherent. Using holotomographic microscopy, we can confirm the difference between all previous generations of monophasic hyaluronic acid fillers and the new Bioxis product.

Follow us on Facebook

Thus, we can prove that another hyaluronic acid filler has several clusters. The preparation seems homogeneous, but thanks to holotomography, it is found that there are some areas in it where the arrangement of hyaluronic acid is more or less dense relative to the main mass.

In Cytosial injectable preparations there is no heterogeneity, additional components, clusters or denser areas, hyaluronic acid is homogeneous. And that is why working with such a filler is called "velvet technology".

What are the clinical benefits of homogeneous hyaluronic acid

B. RS: At first glance, you won't see an incredible difference. But closer attention will allow you to discover that we do not use lidocaine, but the injections are virtually painless.

During the extrusion of the heterogeneous part of the hyaluronic acid, you need to apply more force, which forms an uneven pressure throughout the injection of the filler. The occurrence of pressure peaks and uneven injection flow leads to painful sensations, which is extremely unfavorable for patient comfort.

Next Generation Hyaluronic Acid: Premium Dermal Fillers

Homogeneous hyaluronic acid has a homogeneity that allows you to inject the filler always with the same pressure, you don't create peaks.

Therefore, with Cytosial without lidocaine, we create almost the same patient comfort as with a product containing lidocaine.

Is the safety of using new generation hyaluronic acid increasing

B. RS: We know that with modern injection techniques, we have an increasing number of vascular complications. The first sign of a vascular complication (before you see color change, livedo) is pain.

But with drugs that contain lidocaine as a local anesthetic that works in milliseconds, the patient will not feel pain if you hit the vessel.

An important safety benefit is the use of hyaluronic acid without lidocaine.

If you hit the vessel, the patient will immediately feel pain, and you will be able to stop and react much faster than with other fillers. Therefore, this fact testifies to the great advantage of Cytosial Why did you choose this particular product

: I know one company that offers more than 20 fillers. With such a large selection, it is more difficult for doctors to find the right product. BIOXIS Pharmaceuticals offers 3 different products, with one more coming in about 1-1.5 years. So there will be 4 products available, which I think is enough to give clinicians the ability to select the

without creating confusion. Thus, a significant advantage for physicians is the fact that they can only choose between 4 products that are designed for specific purposes. Another significant difference between the Bioxis line and the fillers available on the market is the same amount of HA in all products. Other companies, while playing with the viscosity and elasticity of the gel, always play with the amount of HA and the degree of crosslinking. Thanks to the linearization of hyaluronic acid chains, in order to change the elasticity and viscosity of the products, we change only the degree of its cross-linking. Thus, the amount of HA (25 mg) is the same in each syringe of Cytosial Deep Wrinkles, Medium and Volume. But at the same time, the BDDE crosslinker in the Cytosial Volume fillers is 2.15% – this is a meager amount for a volumizing product. The best volumizing filler I know of contains over 4% BDDE. We managed to reduce its number by half. Cytosial Deep Wrinkles has a BDDE of 1.5% and Cytosial Medium – 1.15%. At the same time, HA is cross-linked, stable and homogeneous, which is proved by holotomography. This is truly a revolution in HA fillers.

What additional components are included in the Cytosial fillers

Products Cytosial – pure cross-linked hyaluronic acid without any impurities. And this is also important in the context of security. The more ingredients the preparation contains, the higher the risk of a negative reaction of the patient to any of them.

What results can I get with Cytosial

The results of using Cytosial are the same as with other fillers. However, I can say that it takes less product to get them. It's hard to prove, but one 1.1 ml Cytosial syringe provides the same effect as the one and a half filler syringes that I used before.

We remind you that "Steam Pharma

exclusively brings to the market an innovative line of Cytosial fillers. Thank you for staying with estet-portal.com. Read other interesting articles in the "Cosmetology" section. You may be interested in Secrets of successful face correction with fillers from Dr. Wolfgang Radish-Svoboda

What is the essence of the revolution in the field of injection cosmetology

BIOXIS pharmaceuticals is in the esthetic market with a completely new idea. In this case they were working with the hyaluronic filler. Of course, if you come out with a new product it should have an advantage to all the others on the market. And that is what BIOXIS pharmaceuticals did. They have a new philosophy that they found out. The hyaluronic acid (HA) range before with long chains is like a 3D-network where the chains are in a composition like a wool ball. And Bioxis found out, if we lengthen the chains and put it in a control straight version, HA gels become smoother, more homogeneous. And we can prove it. When we use holo-tomographic microscopy, we can show the difference between all the fourth and fifth generation of monophasic hyaluronic acid gels and the new Cytosial range of Bioxis.

So you can see that in former formulations HA forms some clusters. They seem to be homogeneous but in the holo-tomographic view we can see that they have some spots, where the composition of HA is more dense and some parts where it is not as dense. And when you compare it with Cytosial range it is really smooth, there are no compositions, no compounds of hyaluronic acid, no clusters or more dense areas. Everything is very smooth and homogenous. And that is why we call it velvet technology.

Compared with the other ranges, we now have one point – this smoothness, this homogeneity which now is a big difference to the other ranges. We need less BDDE which, as we know, is a toxic substance. So the lower the cross linker BDDE is, the less risk of a side effect, a reaction to the product. And that’s the technology of Bioxis.

What are the benefits of homogenous hyaluronic acid for the clinical practice

At the first view, you will probably not see an incredible difference. But second view is we are not using lidocaine, and the injections are almost painless. This means that the homogeneity allows you to inject always with the same pressure, and you don`t have some peaks which appear during injection with inhomogeneous part when you have to press a little bit more and the product comes out under greater pressure and makes peak , which is so painful. Therefore, without lidocaine in Cytosial we have almost the same comfort for the patient than a product with lidocaine.

Does filler's safety increase

We know that with the injection technique that we are using now we have an increasing number of vascular complications. The first sign of a vascular complication (before you see the discoloration, livedo) is pain. But with the all products which consist of lidocaine as a local anesthetic, which is working with a milliseconds, the patient doesn`t feel any pain if you are intravascular. So it is a safety reason as well if you are using a HA without lidocaine: if you are intravascular, the patient will realize it immediately by pain and you can stop and react much faster than before. So this is the big benefit of this range.

I know one brand which has more than 20 filler products. For the doctors it is a little bit complicated to find the right product. At the moment we have 3 different products, we will get another one in the next 1–1.5 years. So with four products, I think, we’ll have enough to give the doctors the right product for the right procedure without making confusion. So this is also a significant benefit and it is more comfortable for the doctors, they can choose products that are intended for volume/medium/deep wrinkles. It is very clear and simple to use a product you need. What is also a big difference is that in the Bioxis range with all products which we are using or producing right now we have the same amount of HA. All other companies when playing with viscosity and elasticity are always playing with the amount of HA and the amount of cross linking. As we have linearized our HA chains we only change the cross linking rate. So only by changing the cross linking rate we change the elasticity and the viscosity of our products. We don’t need to differentiate the amount of the HA; we have 25 mg in every syringe, in every range: volume, medium and deep wrinkles. But the cross linker is 2.15% in volume: 2.15% of BDDE – this is nothing for volumizing product. The best volumizer on the market I know right now has more than 4%. And we are half off the former formulation on the market. The deep wrinkle has 1.5% BDDE and the lowest one, the medium, has 1.15% BDDE cross linker. This is almost nothing and this is cross linked HA, and it is stable, and it is homogenous, and you can prove the homogeneity by the holo-tomographic microscopy. So this is a big revolutionary change in the HA ranges.

We don’t have additional components. It’sa pure cross linked HA. Also this is for safety reasons. The more you add to a product, the higher the risk that a patient could react to something.

At the end we achieve results as with all HA fillers. What I can tell is I think that I am using less product for the same result compared with others. It is difficult to prove but with one syringe (1.1 ml) I have the same result that I could get with 1.5 syringe of former product I was using.

Share: